IDiyas

For the Inventor, By the Inventor

Knoxville, TN, United States of America

Provectus Pharmatech, Inc


USPTO Granted Patents = 25



Trademarks = 2

Forward Citations = 81

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Eric A Wachter (23 out of 47 patents)

silverMedal H Craig Dees (13 out of 31 patents)

bronzeMedal Timothy C Scott (11 out of 31 patents)

4.  Jamie Singer (9 out of 12 patents)

5.  Aru Narendran (8 out of 8 patents)

6.  John T Smolik (6 out of 13 patents)

7.  Satbir Thakur (5 out of 5 patents)

8.  Lucy Swift (5 out of 5 patents)

9.  Chunfen Zhang (5 out of 5 patents)

10.  Mohit Jain (5 out of 5 patents)

11.  Walter G Fisher (5 out of 17 patents)

12.  Dominic Rodrigues (5 out of 5 patents)

13.  Craig J Eagle (3 out of 4 patents)

14.  Edward V Pershing (3 out of 3 patents)

15.  Bruce Horowitz (3 out of 3 patents)


25 patents:

1. 12377068 - In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors (2025-08-05),
2. 12133840 - Halogenated xanthene composition and method for treating hematologic cancers (2024-11-05),
3. 12064507 - Composition and method for oral treatment of leukemia (2024-08-20),
4. 11975106 - Uses of halogenated xanthenes in oncology and virology (2024-05-07),
5. 11974980 - In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors (2024-05-07),
6. 11938182 - Halogenated xanthenes as vaccine adjuvants (2024-03-26),
7. 11426379 - Combination of local and systemic therapies for enhanced treatment of dermatologic conditions (2022-08-30),
8. 11419844 - Halogenated xanthene composition and method for treating hematologic cancers (2022-08-23),
9. 11071781 - Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer (2021-07-27),
10. 11058664 - In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors (2021-07-13),
11. 10471144 - Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer (2019-11-12),
12. 10130658 - Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound (2018-11-20),
13. 9839688 - Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer (2017-12-12),
14. 9808524 - Combination of local and systemic immunomodulative therapies for melanoma and liver cancer (2017-11-07),
15. 9422260 - Process for the synthesis of 4,5,6,7-tetrachloro-3',6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one(Rose Bengal) and related xanthenes (2016-08-23),
Provectus Pharmatech, Inc. is a biotechnology company specializing in the discovery and development of novel cancer therapies. With a focus on precision medicine, Provectus Pharmatech aims to improve patient outcomes and quality of life. Through comprehensive research and innovative technologies, the company develops proprietary oncology drugs that target specific cancer types and improve treatment efficacy. Utilizing advanced platforms and collaborations, Provectus Pharmatech rapidly progresses its pipeline of promising drug candidates towards clinical trials. For more information on Provectus Pharmatech and its groundbreaking cancer research, please visit their website.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

25 Patents

#9 in Knoxville, TN

#123 in Tennessee

#12,903 in US

#24,910 in the World

...
Knoxville, TN, United States of America

Provectus Pharmatech, Inc

Forward Citations = 81

34 inventors:

goldMedal Eric A Wachter (23 out of 47 patents)

silverMedal H Craig Dees (13 out of 31 patents)

bronzeMedal Timothy C Scott (11 out of 31 patents)

4.  Jamie Singer (9 out of 12 patents)

5.  Aru Narendran (8 out of 8 patents)

Please report any incorrect information to support@idiyas.com
Loading…